PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
|Articles|December 1, 2008
Todd L. Cecil
Todd L. Cecil
Advertisement
Todd L. Cecil
Vice-President,
Compendial Science,
United States Pharmacopeia
Todd L. Cecil, PhD, is the vice-president of compendial science at USP. He has been with the organization since 1993 and has held the following positions: director of noncomplex actives and general policies and requirements; project manager of new monograph development project; scientist; and chemist III.
Cecil is presently a member of the American Association of Pharmaceutical Scientists (AAPS) and ACS. While at AAPS, he has held the positions of secretary treasurer, vice-chair, chair-elect, chair, and past-chair of the APQ Section of AAPS; chair APQ Workshop Committee; and AAPS APQ lead paper screener. He is the author of seven publications and has made more than 60 national and international presentations.
He holds a BS in chemistry from the University of Iowa and a PhD in analytical chemistry from Virginia Commonwealth University.
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement